Himalaya Nutravedics

Founded in 2022, Himalaya Nutravedics has rapidly evolved into a specialized player in the Ayurvedic and nutraceutical space. The company focuses on the intersection of traditional Ayurveda and modern nutraceutical science to provide healthcare solutions across various therapeutic categories.

Its core business model involves the formulation, manufacturing, and marketing of a diverse product portfolio. This includes Softgel Capsules, Tablets, Medicated Oils, Liquid Orals, Hardgel Capsules, and Protein Powders, targeting areas such as digestive health, immunity, metabolic health, and pain management.

The company employs a multi-channel distribution strategy, selling through its own brands as well as leveraging professional networks of doctors, hospitals, clinics, and pharmacists. Its market reach has expanded significantly, currently spanning across 17 Indian states and one union territory.

Operationally, the firm maintains a WHO-GMP certified manufacturing facility located in Hyderabad, Telangana. This facility provides integrated multi-dosage manufacturing capabilities, allowing the company to maintain strict quality standards and scale production efficiently.

The promoter group consists of Rohit Asawa, Divya Asawa, Chanda Asawa, and Rama Raju Penmatsas, who have steered the company from its inception in 2022 to its current scale of operations.

The Himalaya Nutravedics IPO is a book-built issue seeking to raise approximately ₹26.50 Crores through a 100% fresh issue of equity shares. The price band is set between ₹100 and ₹106 per share, with a minimum retail lot size of 2400 shares costing ₹2,54,400. The issue is scheduled to open on September 22, 2026, and close on September 24, 2026, with listing on the BSE SME exchange on September 29, 2026.

The proceeds from the fresh issue are earmarked for strategic growth, with ₹13.75 Crores allocated for funding working capital requirements and ₹7.50 Crores dedicated to business development and digital marketing activities to enhance brand visibility.

Financial performance has shown an aggressive upward trajectory. Revenue grew from ₹14.43 Crores in FY24 to ₹21.00 Crores in FY25, and surged to ₹43.12 Crores in FY26. Similarly, PAT increased from ₹0.43 Crores (FY24) to ₹2.23 Crores (FY25), reaching ₹7.39 Crores in FY26, indicating strong operational scalability.

From a valuation perspective, the company reports a basic EPS of ₹12.05 for FY26. While a specific P/E is not provided in the dossier, the company demonstrates high efficiency with an ROE of 63.87% and a healthy ROCE of 36.41%. Comparison with peers like Jeena Sikho Lifecare and Sandu Pharmaceuticals shows a competitive landscape in the wellness sector.

Key strengths include the WHO-GMP certified facility, integrated manufacturing capabilities, and rapid revenue growth. However, investors should note the risks associated with being a relatively young company (founded 2022) and the high concentration of promoter holding.

Overall, the IPO offers a growth story in the wellness sector. While the financials are robust, the current lack of institutional subscription and flat GMP suggest a cautious approach for short-term listing gains, though the long-term outlook remains tied to business expansion.